CRD3874

DRUG2 trials

Sponsors

Memorial Sloan Kettering Cancer Center, University of Maryland, Baltimore

Conditions

Acute Myeloid LeukemiaMerkel Cell CarcinomaSarcoma

Phase 1

A Study of CRD3874-SI in People With Solid Tumors

RecruitingNCT06021626

Memorial Sloan Kettering Cancer CenterMerkel Cell Carcinoma, Sarcoma

Start: 2023-08-25End: 2029-08-01Target: 81Updated: 2026-08-13

2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML

SuspendedNCT06626633

University of Maryland, BaltimoreAcute Myeloid Leukemia

Start: 2024-08-26End: 2028-01-31Updated: 2026-03-12

Related Papers

Systemic third generation allosteric STING agonist CRD3874-SI, a novel immunotherapy, in patients with advanced solid tumors: Results from a single-agent phase I study.

Journal of Clinical Oncology2026-05-27

Abstract CT191: Intravenous infusion of the allosteric small molecule STING agonist CRD3874-SI in patients with relapsed or refractory acute myeloid leukemia: A phase I trial

Cancer Research2025-04-25

Phase I trial of CRD3874-SI, a systemically administered STING agonist, in patients with advanced solid tumors.

Journal of Clinical Oncology2024-06-012 citations

Abstract 7481: The allosteric STING agonist CRD3874 is systemically tolerated demonstrates systemic tolerability

Cancer Research2024-03-22

P01.09 CRD3874-SI: a novel allosteric STING agonist with high systemic tolerability

Poster presentations2024-03-01

782-D Systemic delivery of novel, allosteric STING agonist CRD3874-SI leads to robust anti-cancer activity by generating pro-inflammatory Type I IFN signals while blocking proton channel mediated toxicity

2023-10-31